The Role of Medical Affairs/Medical Safety in Medical Device Post-Market Risk Assessment & Management
Guide and templates for Medical Affairs input into MedTech Health Hazard Assessment
Guide and templates for Medical Affairs input into MedTech Health Hazard Assessment
The Medical Affairs Professional Society (MAPS) is pleased to share the 2025 Medical Affairs Launch Readiness and Execution Benchmark Report. This report is based on findings from 28 leading organizations across Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the role of Medical in product launch, current and future challenges, and the capabilities required to succeed in the future.
In this webinar, a panel of experts will share their current experiences, challenges, and perspectives on tracking and interpreting the broader impact of scientific content.
In this On-Demand webinar, we explore the recently released MAPS Standards & Guidance (S+G) documents, “Measuring Value and Impact in Medical Affairs” and “Strategic Medical Planning Guide.”
In this On-Demand webinar, we explore the recently released MAPS Standards & Guidance (S+G) documents, “Measuring Value and Impact in Medical Affairs” and “Strategic Medical Planning Guide.”
Join experts from Enago Life Sciences to learn best practices for navigating the balance between efficiency and authority in expedited publishing.
As Med Ed teams adopt new tech, it’s key to know how physicians prefer learning. This article shares 2025 MAPS tips with simple “do THIS, not THAT” strategies.
This article summarizes insights from a 2025 MAPS Roundtable where Medical Affairs leaders discussed emerging trends in digital engagement, focusing on the rise of Digital Opinion Leaders (DOLs) and strategies for Healthcare Professional (HCP) influence mapping. The conversation highlighted how innovative approaches are reshaping disease awareness and stakeholder relationships.
In this On-Demand webinar, you will focus on key learnings from the pilot and explore expansion in usage of this emerging technology.
The objective of this article is to discuss the paradigm shift in how companies plan for and deliver on the “long tail” of a drug’s impact even after Loss of Exclusivity (LoE) – a process known as lifecycle management (LCM).
